New research from the STREAM-1 and -2 clinical trials underscores a critical window for treating ST-elevation myocardial infarction (STEMI)—a severe heart attack caused by a completely blocked artery. Although the benefits of reperfusion (restoring blood flow) are known to be time-dependent, this study focused on the specific clinical outcomes of performing primary percutaneous coronary intervention (PPCI)—an emergency procedure to open blocked arteries using a balloon and stent—within 60 minutes from the time of study randomization.
The analysis evaluated early presenting STEMI patients from the STREAM-1 and -2 trials who sought care within three hours of symptom onset—many of whom were first randomized in ambulances or community hospitals. Researchers found that these early-presenting patients treated with PPCI within 60 minutes experienced significantly better outcomes. Most notably, rapid treatment led to a 62% reduction in cardiogenic shock, a life-threatening condition where the heart suddenly cannot pump enough blood to meet the body’s needs. These patients were also less likely to show Q waves on their discharge ECGs. Q waves often signal permanent heart muscle death, and their absence suggests myocardial salvage, or the successful saving of heart tissue.
Overall, patients treated early saw a substantially lower 30-day risk of adverse outcomes, including death, heart failure, and repeat heart attacks. This benefit was primarily driven by a 70-minute reduction in total ischemic time—the duration the heart muscle is deprived of oxygen—compared to the later-treated group. These results suggest that achieving a first medical contact-to-PPCI time of under 60 minutes dramatically improves both short-term recovery and one-year survival rates. Paradoxically, the 326 patients who underwent PPCI within 60 minutes of randomization represented 29% of the overall PPCI population: notably they were intended to be compared to those undergoing pharmacoinavsive therapy with tenecteplase. However, this cohort was not adherent to the study protocol, which specified they should not be randomized if they were able to undergo PPCI within 60 minutes.
Ultimately, prioritizing PPCI access within 60 minutes of first medical contact is the preferred approach for all STEMI patients, especially in early presenting patients. To maximize clinical benefits and improve survival rates, healthcare providers must implement rigorous system-of-care strategies that proactively eliminate treatment delays.
Reflecting on the study’s impact, Dr. Paul Armstrong notes: “We believe that the current ACC/AHA STEMI guidelines recommending a 90-minute window from first medical contact in such patients is too liberal and deserves reconsideration in the light of our findings”
This study was co-authored by the CVC’s Paul Armstrong, MD; Kevin Bainey, MD, MSc; Yinggan Zheng, MA, MEd; Robert Welsh, MD; and Cynthia Westerhout, PhD, alongside Peter Sinnaeve, MD, PhD and Frans Van de Werf, MD, PhD (KU Leuven). ECG measurements were conducted by the CVC ECG Core Laboratory.
